Key facts
- Prices for laboratory monkeys in China have reached their highest point since the COVID-19 pandemic.
- The surge in prices is attributed to increased demand from pharmaceutical companies for drug research and development.
- This demand is linked to the acceleration of new drug discovery and the need for preclinical testing.
Prices for laboratory monkeys in China have surged to their highest levels since the COVID-19 pandemic, fueled by a robust demand for drug research and development. The escalating costs reflect an increased need for these animals in preclinical testing as pharmaceutical companies worldwide accelerate their efforts in discovering and developing new medications.
The heightened demand signifies a broader trend in the pharmaceutical industry's commitment to innovation and the critical role that animal models play in the early stages of drug development. As more research initiatives commence, the supply chain for these specialized research animals is being tested, leading to price increases.